1. Draw 0.5 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; gently swirl to dissolve (do not shake vigorously).
3. Label with reconstitution date and refrigerate at 2 to 8 °C, protected from light.
4. Wipe vial stopper with alcohol before each use; use a new sterile needle and syringe for each injection. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe.

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds to GHRH receptors on pituitary somatotropes, stimulating endogenous pulsatile GH secretion. Unlike exogenous GH administration, sermorelin preserves physiologic feedback loops: GH release is subject to normal negative feedback via somatostatin and IGF-1, reducing the risk of excessive GH or IGF-1 levels. This pulsatile GH output then promotes hepatic and peripheral IGF-1 production, supporting anabolic processes such as protein synthesis, lipolysis, and tissue repair. Pediatric studies in idiopathic GH deficiency demonstrated significant improvements in height velocity over 6 to 12 months of nightly subcutaneous therapy at 30 mcg/kg. In adults, off-label use aims to restore age-related declines in GH output, though robust adult trial data are limited. Sermorelin requires a functional pituitary to be effective and will not work in cases of pituitary damage or primary GH gene defects.

• Stimulates endogenous pulsatile GH release, supporting physiologic IGF-1 elevation.
  Pediatric GH deficiency: significant improvements in height velocity and growth parameters over 6 to
  12 months.
• Adults (off-label): may support favorable changes in body composition, energy, recovery, and metabolic
  markers (evidence limited; effects more modest than direct GH therapy).
• Preserves physiologic feedback, reducing risk of supraphysiologic GH or IGF-1 levels compared to
  exogenous GH.
• Injection-site reactions: transient redness, pain, or swelling at injection site (~17% incidence in trials).
• Rare systemic effects (under 1%): headache, flushing, dizziness, hyperactivity, drowsiness, or hives.
  Thyroid considerations: ~6.5% of patients developed subclinical hypothyroidism in one study;
  untreated hypothyroidism can blunt GH response.
• No serious acromegaly, hypoglycemia, or excessive IGF-1 elevations reported at recommended
  dosages.